Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous group of liver diseases
characterized by the accumulation of fat in the liver. The heterogeneity of NAFLD is reflected …

Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …

Practitioners of ancient societies from the time of Hippocrates and earlier recognized and
treated the signs of inflammation, heat, redness, swelling, and pain with agents that block or …

Aging is a complex phenomenon characterized by the progressive loss of tissue and organ
function. The oxidative-stress theory of aging postulates that age-associated functional …

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing worldwide, yet there
are no effective treatments. A decade has passed since the initial lipidomics analyses of liver …

Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …

Non-alcoholic fatty liver disease—the most common chronic liver disease—encompasses a
histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) …

The acute inflammatory response is host-protective to contain foreign invaders. Many of
today's pharmacopeia that block pro-inflammatory chemical mediators can cause serious …

Unresolved inflammation is a major contributor to the development of heart failure following
myocardial infarction (MI). Pro-resolving lipid mediators, such as resolvins (eg RvD1), are …